Tekla Life Sciences Investors (HQL) stock: key figures, P/E, revenue and dividend

Financials · Asset Management & Custody Banks · United States · ISIN US87911K1007

Price
18.66 USD
Market cap
538.76 m USD
P/E (2025)
6.29
P/S (2025)
6.24
Dividend yield
12.00 %
Net margin
99.08 %
Return on equity (ROE)
16.66 %
Return on assets (ROA)
16.61 %

Tekla Life Sciences Investors financials

Fiscal year20242025
Revenue86.69 m USD86.39 m USD
Gross profit86.69 m USD86.39 m USD
Operating income85.30 m USD85.59 m USD
EBIT85.30 m USD–
Net income85.30 m USD85.59 m USD
Diluted EPS – continuing operations3.04 USD2.96 USD

Full history since 1996, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Tekla Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.